ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Nitto Denko, Bristol-Myers team up on cirrhosis drugs

OSAKA -- Nitto Denko will partner with U.S. pharmaceutical giant Bristol-Myers Squibb to develop and sell next-generation biomedicine for advanced liver fibrosis set to go on the market as early as 2018, the latest in an array of promising drug candidates coming out of Japan.

Nitto Denko controls roughly 60% of the global market for manufacturing of nucleic acid drugs. In June 2013, the Osaka-based company began U.S. clinical trials of a treatment that inhibits genetic activity linked to liver fibrosis. No effective drugs apparently exist to treat cirrhosis, or advanced liver fibrosis, which afflicts an estimated 6 million people worldwide.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more